What is Accuray?
Accuray is a leader in the development and manufacturing of advanced radiation oncology systems, providing clinicians with the tools necessary to target tumors with high precision while sparing healthy tissue. The company's core value proposition lies in its integration of real-time imaging, adaptive treatment planning, and high-fidelity delivery technologies. These systems are essential for hospitals and specialized cancer centers that require the flexibility to adjust therapy protocols in response to anatomical changes during a patient's treatment course. By addressing the critical balance between treatment efficacy and patient quality of life, Accuray has established itself as a cornerstone provider in the global oncology market, supporting the management of malignancies across diverse anatomical sites.
How much funding has Accuray raised?
Accuray has raised a total of $500M across 5 funding rounds:
Stock Offering
$288M
Debt
$70M
Debt
$52M
Debt
$40M
Debt
$50M
Stock Issuance/Offering (2007): $288M, investors not publicly disclosed
Debt (2016): $70M led by Cerberus Business Finance, LLC
Debt (2017): $52M supported by MidCap Financial Trust
Debt (2017): $40M featuring MidCap Financial Trust
Debt (2025): $50M backed by Wingspire Capital
Key Investors in Accuray
Wingspire Capital
Wingspire Capital is a diversified specialty finance firm that provides innovative, one-stop financing solutions for middle market companies, focusing on asset-backed loans.
MidCap Financial Trust
MidCap Financial Trust is a middle-market-focused lender that provides senior debt solutions to companies across various industries, including healthcare.
Cerberus Business Finance, LLC
Cerberus Business Finance is an affiliate of a global private equity firm, specializing in providing direct lending and credit solutions to middle-market businesses.
What's next for Accuray?
Looking ahead, Accuray is well-positioned to leverage its recent capital influx to accelerate the next generation of adaptive radiotherapy solutions. The strategic focus will likely center on enhancing the software-driven capabilities of its existing platforms, further integrating artificial intelligence to streamline treatment planning and delivery. As the company continues to scale, the emphasis will remain on expanding its footprint in emerging healthcare markets and deepening its relationships with major clinical research institutions. By maintaining a disciplined financial strategy, Accuray is prepared to navigate the evolving regulatory and technological demands of the oncology sector, ensuring long-term value creation for stakeholders and improved clinical outcomes for patients worldwide.
See full Accuray company page
